These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18253741)

  • 61. The Comparison of Thermal Effects of a 1940-nm Tm:fiber Laser and 980-nm Diode Laser on Cortical Tissue: Stereotaxic Laser Brain Surgery.
    Tunc B; Gulsoy M
    Lasers Surg Med; 2020 Mar; 52(3):235-246. PubMed ID: 31592541
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Devitalization of lens epithelium cells by dye-enhanced therapy].
    Joussen AM; Kruse FE; Rohrschneider K; Völcker HE
    Ophthalmologe; 1995 Aug; 92(4):581-90. PubMed ID: 7549352
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
    Wen YH; Ho A; Patil S; Akram M; Catalano J; Eaton A; Norton L; Benezra R; Brogi E
    Breast Cancer Res Treat; 2012 Aug; 135(1):93-102. PubMed ID: 22538771
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A study of cytokeratin profiles in localized cutaneous amyloids.
    Chang YT; Liu HN; Wang WJ; Lee DD; Tsai SF
    Arch Dermatol Res; 2004 Jul; 296(2):83-8. PubMed ID: 15141317
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cytokeratin expression pattern in congenital and acquired pediatric cholesteatoma.
    Olszewska E; Lautermann J; Koc C; Schwaab M; Dazert S; Hildmann H; Sudhoff H
    Eur Arch Otorhinolaryngol; 2005 Sep; 262(9):731-6. PubMed ID: 15754169
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mucosubstance histochemistry and pathogenesis of acquired cholesteatoma.
    Nagai T; Suganuma T; Ide S
    Eur Arch Otorhinolaryngol; 2007 Jul; 264(7):749-53. PubMed ID: 17287952
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Indocyanine green-augmented diode laser treatment of port-wine stains: clinical and histological evidence for a new treatment option from a randomized controlled trial.
    Klein A; Szeimies RM; Bäumler W; Zeman F; Schreml S; Hohenleutner U; Landthaler M; Koller M; Babilas P
    Br J Dermatol; 2012 Aug; 167(2):333-42. PubMed ID: 22435991
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [The research progress of keratin's roles in the pathology of middle ear cholesteatoma].
    Feng YS; Si Y; Zhang ZG
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Nov; 54(11):870-874. PubMed ID: 31795552
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Immunohistochemical detection of c-myc proto-oncogene products in middle ear cholesteatoma].
    Holly A; Sittinger M; Bujía J
    Laryngorhinootologie; 1995 Jun; 74(6):348-51. PubMed ID: 7662077
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Immunomorphological evaluation of cholesteatoma].
    Kuczkowski J; Bakowska A; Mikaszewski B
    Otolaryngol Pol; 2004; 58(2):289-95. PubMed ID: 15307474
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Expression of cytokeratins 13 and 16 in middle ear cholesteatoma.
    Sasaki H; Huang CC
    Otolaryngol Head Neck Surg; 1994 Mar; 110(3):310-7. PubMed ID: 7510866
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Performance of the 808-nm diode laser on equine upper airway tissue is enhanced by intravenous administration of indocyanine green.
    Tate LP; Blikslager AT; Papich MG
    Photomed Laser Surg; 2007 Oct; 25(5):443-8. PubMed ID: 17975959
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Roles of cytokines and cell cycle regulating substances in proliferation of cholesteatoma epithelium.
    Tanaka Y; Kojima H; Miyazaki H; Koga T; Moriyama H
    Laryngoscope; 1999 Jul; 109(7 Pt 1):1102-7. PubMed ID: 10401849
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Expression of hypoxia inducible factor 1 alpha and Von Hippel Lindau protein in human middle ear cholesteatoma.
    Adunka O; Gstoettner W; Knecht R; Kierner AC
    Laryngoscope; 2003 Jul; 113(7):1210-5. PubMed ID: 12838021
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Laser-assisted myringoplasty--technical aspects.
    Pyykkö I; Poe D; Ishizaki H
    Acta Otolaryngol Suppl; 2000; 543():135-8. PubMed ID: 10909002
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Strategies for the treatment of labyrinthine fistula in chronic purulent otitis media with cholesteatoma].
    Patiakina OK; Garov EV
    Vestn Otorinolaringol; 1998; (1):6-9. PubMed ID: 9505523
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Interleukin-1-containing cells in cholesteatoma of the middle ear].
    Schilling V; Bujia J; Negri B; Kastenbauer E
    Laryngorhinootologie; 1992 May; 71(5):271-5. PubMed ID: 1616549
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Current concepts of the pathogenesis of acquired middle ear cholesteatoma].
    Welkoborsky HJ
    Laryngorhinootologie; 2011 Jan; 90(1):38-48; quiz 49-50. PubMed ID: 21225533
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [The changing pattern of stem cell markers of sweat gland in deep partial-thickness burn wound].
    JIANG DY; ZONG XL; FU XB; WANG W; SHAN F
    Zhonghua Shao Shang Za Zhi; 2009 Aug; 25(4):301-4. PubMed ID: 19951551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.